Amifostine trihydrate is potent hypoxia-inducible factor-α1 (HIF-α1) and p53 inducer
Smiles: CC1C(N)=NC(=NC=1C(=O)N[C@@H]([C@@H](O[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](OC(N)=O)[C@@H]1O)C1=CN=CN1)C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O
Smiles: OC1C=C(O)C(=C2OC(=CC(=O)C=12)C1C=CC(O)=CC=1)C1=CC(=CC=C1O)C1=CC(=O)C2=C(C=C(O)C=C2O)O1
is a cyclooxygenase-2 inhibitor used to treat osteoarthritis
with IC50 values of between 2
MK-0354 497 Amifostine trihydrate is potent hypoxia-inducibleMK 0354 is a partial agonist of GPR109a receptor, for hGPR109a mGPR109a with EC50 of 1. 65 1. 08 M, showed no activation of GPR109b. IC50 value: 1. 65 M (EC50, for hGPR109a), 1. 08 M (EC50, for mGPR109a) Target: GPR109ain vitro: MK 0354 demonstrated clear and statistically significant partial agonism in the cAMP assays for both the mouse and human receptors with efficacy approximately 60 70% of that of either nicotinic acid or hydroxy butyrate, a